TSX open
Loading markets…

Advertisement

Investing

SNY vs ONC: which stock is the better value?

By Wealth Awesome -
Stocks & ETFs:SNY.USONC.US

Follow SNY

Photos provided by Pexels

A comparison of Sanofi ADR and BeiGene, Ltd. reveals interesting insights into their valuations.

In the competitive landscape of pharmaceuticals, biotechnology, and life sciences, investors often look for value opportunities. This comparison focuses on two prominent players: Sanofi ADR (SNY) and BeiGene, Ltd. (ONC). By examining their price-to-earnings (P/E), price-to-earnings growth (PEG), and price-to-book (P/B) ratios, we can better understand which stock may offer a more attractive valuation.

Investor takeaway: While Sanofi ADR appears cheaper on several valuation multiples, it's essential to consider the broader context of each company's performance and market position before making investment decisions.

Advertisement

Stocks in this list

Live snapshots — open any name for the full quote and Wealth Awesome price forecast.

Advertisement

Valuation Comparisons

Advertisement

Sanofi ADR screens cheaper on P/E and P/B ratios, while BeiGene has a more attractive PEG ratio, illustrating a split in the valuation landscape.

Bull case

Sanofi ADR presents a more appealing valuation with a P/E of 20.9 and a dividend yield of 10.28%. This suggests potential income for investors. Analysts generally recommend a 'Buy' rating, with a target price of US$53.61, indicating optimism about its future performance.

Bear case

BeiGene, Ltd. has a higher P/E of 62.4, reflecting its growth potential in the biotechnology sector. Although it doesn’t pay dividends, the strong analyst consensus of 'Strong Buy' and a target price of US$435.53 show confidence in its long-term prospects.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: October 14, 2026
Last Updated: October 14, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement